Furthermore, the anti-tumor effects of 30 pmol CgA were significantly inhibited by anti-PN1 antibodies, but not by control antibodies in both fibrosarcoma and adenocarcinoma models (Figure 8E). The gene discussed is CGA; the disease is adenocarcinoma.